Phase 1 Trial of Navitoclax and Sorafenib in Patients with Relapsed or Refractory Solid Tumors with Hepatocellular Carcinoma Expansion Cohort.
Oluwadunni E. Emiloju,Jun Yin,Emily Koubek,Joel M. Reid,Mitesh J. Borad,Yanyan Lou,Mahesh Seetharam,Martin J. Edelman,Edward A. Sausville,Yixing Jiang,Ahmed O. Kaseb,James A. Posey, Sarah L. Davis,Gregory J. Gores,Lewis R. Roberts,Naoko Takebe,Gary K. Schwartz,Andrea E. Wahner Hendrickson,Scott H. Kaufmann,Alex A. Adjei,Joleen M. Hubbard,Brian A. Costello Journal of Clinical Oncology（2024）
关键词
ABT-263,Navitoclax,Sorafenib,BCL2,Hepatocellular carcinoma
AI 理解论文
溯源树
样例
